Thursday, June 24, 2010

Novo Nordisk spent $540K lobbying US gov't in 1Q

Market Commentary and Intraday News
Novo Nordisk spent $540K lobbying US gov't in 1Q
1 day ago

(AP:WASHINGTON) Danish drugmaker Novo Nordisk spent $540,000 lobbying the U.S. government in the first quarter of 2010, addressing drug importation and several diabetes-related issues, among other topics.

The drugmaker also lobbied on patent reform, and to improve access to care and treatment of diabetes patients.

The company's first-quarter total represented a 71 percent jump from the first quarter of 2009 but a slight drop from the $550,000 it spent in the fourth quarter of last year.

Besides Congress, Novo Nordisk lobbied the Patent and Trademark Office, the Department of Health and Human Services, the Centers for Medicare and Medicaid Services, and the Office of Management and Budget.

Among those registered to lobby for Novo Nordisk in the January-March period was Lauren Semeniuk, a former legislative director for Rep. Cliff Stearns, R-Fla., according to a report filed May 25 with the House of Representatives clerk's office.